Table 4 Serious adverse events during 3 years follow-up in the placebo and adipose-derived stromal cell (ASC) group
Serious adverse events | Placebo (n = 20) | ASC (n = 40) | P-value |
|---|---|---|---|
Death | 0 (0) | 4 (10) | 0.291 |
Hospitalizations | |||
Myocardial infarction | 5 (25) | 8 (20) | 0.744 |
Dyspnea | 0 (0) | 1 (2.5) | 1.000 |
Anemia | 2 (10) | 3 (7.5) | 1.000 |
Syncope | 1 (5) | 0 (0) | 0.333 |
Peripheral edema | 0 (0) | 1 (2.5) | 1.000 |
Angina worsening | 12 (60) | 14 (35) | 0.028 |
Pneumonia | 1 (5) | 4 (10) | 0.656 |
PCI | 7 (35) | 6 (15) | 0.101 |
Heart failure | 0 (0) | 4 (10) | 0.291 |
TIA/apoplexia cerebri | 2 (10) | 0 (0) | 0.107 |
Pulmonary embolism | 0 (0) | 1 (5) | 1.000 |
Cancer | 3 (15) | 1 (5) | 0.103 |